Analyst: Time to Sell This Penny Stock

Most analysts are bullish on the biopharma

Jul 16, 2019 at 9:44 AM
facebook twitter linkedin

B. Riley FBR downgraded Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to "sell" from "neutral," and lowered its price target to $1.10 from $1.90 -- a 25% discount to last night's close. In reaction, the penny stock has plunged 4.1% out of the gate to trade at $1.40.

It's already been a tough stretch for the shares of the EpiPen rival, which were down almost 64% year-over-year heading into today's trading. More recently, the stock's rebound off its July 2 record low of $1.20 was quickly contained by familiar resistance at its descending 50-day moving average.

Nevertheless, the majority of the analysts in coverage still maintain a "buy" or better rating on the biopharmaceutical name. Plus, the average 12-month price target sits all the way up at $171.92. More bear notes could be in store for the underperformer.

Elsewhere on the sentiment front, short sellers have been increasing their exposure to the struggling stock. Year-to-date, short interest on ADMP is up 13.4% to 4.08 million shares. This accounts for a healthy 8.7% of the security's available float, or 12.9 times the average daily pace of trading. These bears are sidelined today, though, with the equity on the short-sale restricted list.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners